Keyword: Roivant Sciences
The pair has been studying imeglimin, a new type of drug the partners say is the first clinical candidate in a new chemical class of oral agents.
Cytovant starts out with the Asian rights to two Medigene programs and a partnership to develop two additional T cell receptor treatment programs.
The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.
Enzyvant finds new CEO in former Alexion exec; Arix reappoints CEO after 5-month hunt; and MorphoSys CEO Moroney announces retirement.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
Baselga to helm AstraZeneca’s cancer R&D; ex-Novartis exec joins UroGen; Roche exec moves to Genevant; and Immunocore poaches from AZ’s biologics arm.
Despite a few noticeable high-profile and departures from the Vant constellation of biotechs, Vivek Ramaswamy still lures big guns to his startups.
The deal is the first time Roivant has formed a framework to facilitate the ongoing in-licensing of drugs from a company.
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.